Bestaande gebruiker? Log in
Abonneren
Home
Beurs vandaag
Koersen
Nieuws
Agenda
Analisten
Analisten vandaag
Meest aanbevolen aandelen
Minst aanbevolen aandelen
Aandelen met grootste potentieel
Insider trading
Insiders vandaag
Meest gekochte aandelen
Meest verkochte aandelen
Mijn Trivano
Mijn Trivano
Mijn selecties
Mijn nieuwsbrieven
Abonneren
Beurs vandaag
Koersen
Nieuws
Agenda
Analisten
Insider trading
Mijn Trivano
Registreren / inloggen
Beurs vandaag
Amerika
Seelos Therapeutics Inc
Nieuws
Seelos Therapeutics Inc
SEEL
NAS
: SEEL
| ISIN: US81577F1093
14/11/2024
0,720 USD
(+2,86%)
(+2,86%)
14/11/2024
Aandeel volgen
Aandeel gevolgd
Samenvatting
Nieuws
Insiders
Technische analyse
TA
Toon enkel gratis nieuws
17 mei 2024 ·
Seelos Therapeutics Announces Pricing of $1.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
· Persbericht
14 mei 2024 ·
Seelos Therapeutics Announces 1-for-8 Reverse Stock Split
· Persbericht
29 april 2024 ·
Seelos Therapeutics Announces Strategic Focus on Mental Health Initiatives and Provides an Update on Current Discussions of Potential Partnerships and Collaborations
· Persbericht
19 maart 2024 ·
Seelos Therapeutics Provides Update on Top-Line Results from its Amyotrophic Lateral Sclerosis (ALS) Study with SLS-005 (IV Trehalose)
· Persbericht
26 januari 2024 ·
Seelos Therapeutics, Inc. Announces $4.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
· Persbericht
22 januari 2024 ·
Seelos Therapeutics Announces Receipt of Minutes from its End of Phase II Meeting with the United States Food and Drug Administration (FDA) Highlighting Modifications to the Primary and Secondary Endpoints of its Phase II Study of SLS-002
· Persbericht
2 januari 2024 ·
Leading Independent Proxy Advisory Firm ISS Recommends Seelos Stockholders Vote "FOR" All Proxy Proposals at the Special Meeting to be held on January 10, 2024
· Persbericht
22 december 2023 ·
Seelos Therapeutics, Inc. Releases Letter to its Stockholders
· Persbericht
1 december 2023 ·
Seelos Therapeutics Announces Closing of Public Offering
· Persbericht
27 oktober 2023 ·
Seelos Therapeutics to Present a Poster on SLS-005 in Alzheimer's Disease at Neuroscience 2023
· Persbericht
17 oktober 2023 ·
Seelos Therapeutics Retains Canaccord Genuity in Connection with Review of Potential Partnerships and Collaborations
· Persbericht
28 september 2023 ·
Thinking about buying stock in Oncolytics Biotech, Near Intelligence, Basin Uranium, Seelos Therapeutics, or MillerKnoll?
· Persbericht
28 september 2023 ·
Thinking about buying stock in Seelos Therapeutics, West Red Lake Gold Mines, Immunovant, MSP Recovery, or Transcode Therapeutics?
· Persbericht
27 september 2023 ·
Thinking about buying stock in American Lithium, Avalo Therapeutics, Seelos Therapeutics, Rivian Automotive, or Immunovant?
· Persbericht
27 september 2023 ·
Seelos Therapeutics Announces Encouraging Data from an In Vivo Study of SLS-005 in an Aggressive Preclinical Model of Alzheimer's Disease
· Persbericht
21 september 2023 ·
Seelos Therapeutics Announces Registered Direct Offering of Common Stock and Warrants to Purchase Common Stock
· Persbericht
20 september 2023 ·
Seelos Therapeutics Announces Top Line Results from SLS-002 Phase II Study in Adults with Major Depressive Disorder at Imminent Risk of Suicide
· Persbericht
14 augustus 2023 ·
Seelos Therapeutics Provides Second Quarter 2023 Clinical Update
· Persbericht
22 juni 2023 ·
Seelos Therapeutics Announces the Close of Enrollment of its Registration Directed Study of SLS-002 (Intranasal Racemic Ketamine) for Acute Suicidal Ideation and Behavior (ASIB) in Adults with Major Depressive Disorder (MDD)
· Persbericht
22 mei 2023 ·
Seelos Therapeutics to Participate in Two Upcoming Healthcare Conferences
· Persbericht
Aandeel volgen
Aandeel gevolgd
Mijn selecties
Voorbeeldselectie
Je selectie is nog leeg.
Voeg nu effecten toe